The purpose of this Funding Opportunity is to stimulate new and innovative multidisciplinary research in the area of long acting therapeutics for HIV and HIV-associated tuberculosis (TB) and viral hepatitis B and C.
Safe and efficacious medicines are available for the prevention and treatment of major diseases, but their effectiveness can be compromised by poor treatment completion. Lack of adherence can worsen clinical outcomes, leading to increased mortality, persistent transmission and increased drug resistance in the case of antimicrobials and antivirals. Analyses of treatment and prevention of HIV, malaria, and TB within public health programs show wide disparities in rates of completion, especially among specific populations and regions.
Application Deadline: 23 April 2019
NIH/NIAID: 1F31AI129549-01A1; Amer Al-Khouja; 05/01/17 - 04/30/19
NIH/NIAID: 1R01AI131416-01; Andrew Martin Bellinger (PI); 03/22/17 - 02/28/22
Non-adherence to anti-retroviral therapy by HIV+ patients results in increased viral loads and risk of emergence of drug-resistant HIV strains. This poses a major public health threat. Lyndra Co. has developed an orally available, long-acting drug delivery system that it will now formulate to deliver anti-retrovirals.
In this application, researchers propose to utilize novel synthetic chemistry to develop a series of aliphatic tenofovir prodrugs designed to greatly enhance cellular uptake and to provide prolonged intracellular exposure to molecules with potent antiviral activity. They will further extend systemic exposure to these compounds by delivering them in slow-release nanoparticle formulations. They believe that with this “dual-modulation” of drug presentation we will provide systemic exposure to therapeutic concentrations of highly active antiviral compounds for periods of at least four weeks following intramuscular injection.
NIH/NIMH; 5R01MH106380-02; Sarit A. Golub (PI); 01/16/15 - 11/30/19
NIH/NIAID; 4R01AI073146-09: Victor J. Garcia-Martinez (PI); 05/01/07 - 07/31/17
NIH/NIAID; 5UM1AI120184-02; Thomas Hope (PI); 07/07/15 - 06/30/20
The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications from single institutions, or consortia of institutions, to identify existing anti-HIV molecules...